Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China

Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China

Chengdu, China, December 20, 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that to accommodate its growth and expansion, and on the back of its recent financing, it has relocated to the Tianfu International Biotown, in Chengdu, China. Biotown is the premier biotech research park in Chengdu, the capital of Sichuan province.

The move coincides with the fifth anniversary of the formation of the company based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop.

Dr Yang, President, and CEO of ACB, said: “We are delighted to be part of China’s prestigious Biotown community, as neighbors to pharma companies including AstraZeneca and Johnson & Johnson, and many other innovation-driven biotech companies.”

Commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research, ACB is applying synthetic lethal approaches to develop targeted cancer therapies. These have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics.

“We will continue to make full use of the excellent locational advantages, such as the region’s rich natural product resources, and the local government’s commitment to building up biotech companies, to support our work in translating scientific breakthrough into effective medicines” said Dr Yang.

The new facility is three times larger than the company’s previous site. With a total research space of approximately 40,000 square feet (3,700 square meters) across four floors, the new facilities will include offices and laboratories for Natural Product Library and Natural Product Drug Design, Analytical Chemistry, Pre-formulation Research, DMPK, Computational Chemistry and Drug Design, Cell Culture, HTS/HCS, Target MOA, Pharmacology & Toxicology, Laboratory Animal Resource Center (LARC), Small Animal In vivo Imaging and Medicinal Chemistry.

The internal work equipping the facility began in June 2021 and was completed on December 17. A total of 40 staff works at the Biotown site with a total of 57 employees globally across the company’s sites in China, India, the USA, the UK and Australia. ACB is planning to expand further in coming months and years as it scales up its R&D programs.

In October, ACB announced that it had secured an additional CNY 68.4 million (~USD 10.6 million) from new Chinese investors, led by Three Rivers Capital. The total raised in the seed round is now over USD31 million (around CNY 200 million).

With five drug discovery programs, ACB is progressing rapidly through optimization to candidate selection toward IND enabling studies, with the aim of initiating two clinical trials in the USA in 2022.

“We will be proud to launch our first programmes into human clinical trials from our new corporate headquarters in Biotown” concluded Dr Yang.

For further information please contact

At the company

Anticancer Bioscience

bd@anticancerbio.com